Comparing Filgrastim vs Pegfilgrastim
| Filgrastim | Pegfilgrastim |
|
|---|
| Filgrastim | Pegfilgrastim |
|
|---|---|---|
|
Prescription only
Prescribed for Neutropenia Associated with Chemotherapy, Neutropenia, Aplastic Anemia, Bone Marrow Transplantation, Hematopoietic Syndrome of Acute Radiation Syndrome, Myelodysplastic Syndrome... View more |
Prescription only
Prescribed for Neutropenia Associated with Chemotherapy, Neutropenia Associated with Radiation, Febrile Neutropenia, Hematopoietic Syndrome of Acute Radiation Syndrome. Pegfilgrastim may also be used... View more |
Related suggestions Hematopoietic Syndrome of Acute Radiation Syndrome
Popular comparisons
|
| More about Filgrastim | More about Pegfilgrastim | |
| Ratings & Reviews | ||
|
Filgrastim has an average rating of 8.0 out of 10 from a total of 10 ratings on Drugs.com. 70% of reviewers reported a positive effect, while 20% reported a negative effect. |
Pegfilgrastim has an average rating of 4.9 out of 10 from a total of 77 ratings on Drugs.com. 39% of reviewers reported a positive effect, while 47% reported a negative effect. |
|
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||
|
View all Filgrastim side effects |
View all Pegfilgrastim side effects |
|
| Drug Class | ||
| Generic Availability | ||
|
N/A |
N/A |
|
| Pricing and Coupons * Prices are without insurance | ||
|
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
|
| Dosage Forms | ||
|
N/A |
N/A |
|
| Brand Names | ||
| Neupogen, Nivestym, Nypozi, Releuko, Zarxio | Fulphila, Fylnetra, Neulasta, Nyvepria, Stimufend, Udenyca, Ziextenzo | |
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||
|
5.8 hours |
80 hours |
|
| CSA Schedule 1 View glossary of CSA terms | ||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
|
| Pregnancy Category | ||
|
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
|
| Drug Interactions | ||
|
A total of 174 drugs are known to interact with Filgrastim:
|
A total of 177 drugs are known to interact with Pegfilgrastim:
|
|
| Alcohol/Food/Lifestyle Interactions | ||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
| Disease Interactions | ||
| First Approval Date | ||
|
N/A |
N/A |
|
| WADA Class View classifications | ||
|
N/A |
N/A |
|
| More Information | ||
| Patient Resources | ||
| Professional Resources | ||
| Related Treatment Guide | ||
|
||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Diflucan
Diflucan (fluconazole) is used to treat and prevent fungal infections. Includes Diflucan side ...
Zarxio
Zarxio (filgrastim-sndz) is biosimilar product used to treat neutropenia associated with ...
Tavneos
Tavneos (avacopan) is a C5a receptor antagonist used for severe active ANCA-associated vasculitis ...
Neulasta
Neulasta is used to stimulate neutrophil growth and reduce infection risk (manifested by febrile ...
Neupogen
Neupogen (filgrastim) is used to treat neutropenia, a lack of certain white blood cells caused by ...
Nivestym
Nivestym is used for bone marrow transplantation, neutropenia, neutropenia associated with ...
Fulphila
Fulphila is used for febrile neutropenia, neutropenia associated with chemotherapy
Nplate
Nplate is used to prevent bleeding episodes in people with chronic immune thrombocytopenic purpura ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.